Dimenhydrinate


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Nausea and vertigo caused by Meniere's disease; Treatment and prophylaxis of motion sickness 50-100 mg 6-8 hourly. As prophylaxis for motion sickness: Give 30 minutes to 1 hour prior to activity. Max: 400 mg/day. IV/IM Nausea and vertigo caused by Meniere's disease; Treatment and prophylaxis of motion sickness 50-100 mg 4 hourly . Max: 100 mg 4 hourly.
Dosage Details
Oral
Treatment and prophylaxis of motion sickness, Nausea and vertigo caused by Meniere's disease
Adult: 50-100 mg 6-8 hourly. As prophylaxis for motion sickness: Give 30 minutes to 1 hour prior to activity. Max: 400 mg daily.
Child: 2-6 years 12.5-25 mg 6-8 hourly. Max: 75 mg daily; 6-<12 years 50 mg 6-8 hourly. Max: 150 mg daily; ≥12 years Same as adult dose.

Parenteral
Treatment and prophylaxis of motion sickness, Nausea and vertigo caused by Meniere's disease
Adult: 50-100 mg 4 hourly via IM or slow IV inj over 2 minutes. Max: 100 mg 4 hourly.
Child: 1.25 mg/kg or 37.5 mg/m2 4 times daily via IM inj. Max: 300 mg daily.
Administration
May be taken with or without food.
Reconstitution
IV inj: Dilute a 50 mg vial with 10 mL of 0.9% NaCl soln.
Incompatibility
Incompatible with aminophylline, glycopyrronium bromide, hydrocortisone Na succinate, hydroxyzine, meglumine adipiodone, phenothiazines and soluble barbiturates.
Special Precautions
Patient with history of asthma or lower respiratory tract symptoms (e.g. emphysema, chronic bronchitis), angle-closure glaucoma, prostatic hypertrophy, bladder neck obstruction, stenosing peptic ulcer, pyloroduodenal obstruction, cardiovascular disease (e.g. cardiac arrhythmias, hypertension, ischaemic heart disease), seizure, thyroid dysfunction. Children. Pregnancy and lactation. Hepatic impairment.
Adverse Reactions
Cardiac disorders: Tachycardia.
Ear and labyrinth disorders: Tinnitus.
Eye disorders: Blurred vision.
Gastrointestinal disorders: Dry mouth, nose, throat; epigastric distress, nausea.
General disorders and admin site conditions: Lassitude.
Nervous system disorders: Drowsiness, excitement, headache.
Psychiatric disorders: Nervousness, restlessness, insomnia (children), confusion.
Renal and urinary disorders: Painful urination.
Respiratory, thoracic and mediastinal disorders: Thickening of bronchial secretions.
Skin and subcutaneous tissue disorders: Rash.
IM/IV/Parenteral/PO/Rectal: B
Patient Counseling Information
This drug may cause drowsiness and dizziness, if affected, do not drive or operate machinery.
Overdosage
Symptoms: Drowsiness, hallucination, severe delirium, extrapyramidal symptoms, vomiting, vertigo, convulsions, coma, respiratory depression. Management: May induce emesis or perform gastric lavage within 3 hours after ingestion. Administer oxygen and initiate mechanically assisted respiration in respiratory depression. Administration of vasopressors may be use to treat hypotension. Administer diazepam for convulsions or phenobarbital (5-6 mg/kg) in paediatric patients.
Drug Interactions
Concomitant use with antibiotics may cause ototoxicity and dimenhydrinate may mask ototoxicity symptoms . Enhanced adverse effect (e.g. drowsiness) of other CNS depressants. May prolong and intensify the antimuscarinic effects with MAOIs and other antimuscarinic agents (e.g. atropine, TCA).
Food Interaction
Enhanced CNS depressant effect of alcohol.
Action
Description: Dimenhydrinate, a monoethanolamine derivative, is a sedating antihistamine with antimuscarinic and significant sedative effects. It competes with histamine in binding for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract. It has central anticholinergic activity which blocks chemoreceptor trigger zone, diminishes vestibular stimulation and reduces labyrinth function.
Onset: Antiemetic: Oral: 15-30 minutes; IM: 20-30 minutes.
Duration: 4-6 hours.
Pharmacokinetics:
Absorption: Well absorbed from the gastrointestinal tract . Time to peak plasma concentration: Approx 1 hour.
Distribution: Crosses the placenta and present in breastmilk (small amounts). Volume of distribution: 3-4 L/kg. Plasma protein binding: 70-85%.
Metabolism: Extensively metabolised in the liver to diphenyl-methoxy-ethylamine, diphenyl-methoxy-acetic, and diphenyl-methoxy-N-methylamine.
Excretion: Via urine. Elimination half-life: 5-8 hours.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Dimenhydrinate, CID=10660, https://pubchem.ncbi.nlm.nih.gov/compound/Dimenhydrinate (accessed on Jan. 21, 2020)

Storage
Store between 20-25°C. Protect from light.
MIMS Class
References
Airmit Ace Tablet (Sato Pharmaceutical Co., Ltd). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 16/11/2016.

Anon. Dimenhydrinate. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 16/11/2016.

Anon. Dimenhydrinate. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 15/10/2019.

Buckingham R (ed). Dimenhydrinate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 15/10/2019.

Dimenhydrinate Injection (Fresenius Kabi USA, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 15/10/2019.

Dimenhydrinate Injection, Solution (APP Pharmaceuticals, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 16/11/2016.

Dimenhydrinate Syrup (Sunward Pharmaceutical Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my/. Accessed 15/10/2019.

Dimenhydrinate Tablet (Acme United Corporation). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 15/10/2019.

Dimenhydrinate tablet (Contract Pharmacal Corp). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 16/11/2016.

Dimenhydrinate Tablet (Sunward Pharmaceutical Pte. Ltd.). MIMS Singapore. http://www.mims.com/singapore. Accessed 22/10/2019.

Dimenhydrinate Tablet, Film-coated (Time Cap Labs, Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 16/11/2016.

Pridinate Tablet (Prime Pharmaceutical Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my/. Accessed 15/10/2019.

Disclaimer: This information is independently developed by MIMS based on Dimenhydrinate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Apo-Dimenhydrinate
  • Dimenate
  • Driminate
  • Hydrinate
  • Novomin
  • Pharmaniaga Dimenhydrinate
  • Votmine
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in